Hookipa: $21.25 Million Equity Investment from Gilead

 

• Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share
  
  
• Following the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock
  
  
• Equity investment is to advance the Gilead-partnered HIV therapeutic program through Phase 1; trial expected to commence in the first half of 2024

https://www.globenewswire.com/news-release/2023/12/21/2799897/0/en/HOOKIPA-Pharma-Announces-21-25-Million-Equity-Investment-from-Gilead-Sciences.html